- Q3 net loss widened to $8.9M versus $7.4M in prior-year quarter.
- EPS of $(0.26) vs $(0.60) reflects significant share count dilution (34.0M vs 12.3M shares).
- Presented 36-week and 16-week off-drug data from Part B of SIGNAL-AA study.
Signal #128785 · SEC 8-K
$QTTB SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $QTTB filing catalyst
Why did $QTTB trigger an AI stock catalyst alert?
$QTTB triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: Q32 Bio Reports Q3 2026 Net Loss of $8.9M, Highlights Clinical Trial Data. Key points: - Q3 net loss widened to $8.9M versus $7.4M in prior-year quarter. - EPS of $(0.26) vs $(0.60) reflects significant share count dilution (34.0M vs 12.3M shares). - Presented 36-week and 16-week off-drug data from Part B of SIGNAL-AA study.
How did $QTTB stock react after the SEC filing?
After the SEC 8-K for $QTTB, observed market reaction: T0 price $8.76. Past moves do not guarantee future results.
Where can I get real-time $QTTB SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $QTTB via Telegram and the VIP Web Terminal from €10/month.